Psychiatric Etiologies and Approaches in Altered Mental Status Presentations: Insights from Consultation Liaison Psychiatry

Abstract

Consultation liaison psychiatrists are frequently asked to evaluate patients with altered mental status (AMS). Psychiatrists have unique perspectives and approaches to care for confused patients, particularly optimizing facilitation of care and maintaining vigilance for diagnostic overshadowing. Psychiatrists also offer expertise in primary psychiatric illnesses that can overlap with AMS, and the most common etiology of AMS is delirium. In this article, we provide a consultation liaison psychiatrist perspective on AMS and related psychiatric conditions in addition to delirium. Manic and psychotic episodes have primary and secondary etiologies, with some symptoms that can overlap with delirium. Catatonia, neuroleptic malignant syndrome, and serotonin syndrome are potentially fatal emergencies, and require prompt index of suspicion to optimize clinical outcomes. Trauma sequelae, functional neurologic disorders, and dissociative disorders can present as puzzling cases that require psychiatric facilitation of care. Additionally, AMS is sometimes due to substance intoxication and withdrawal in the hospital. A nonstigmatizing approach to evaluation and management of delirium and AMS can ensure optimal patient care experiences and outcomes.

Keywords

altered mental status - delirium - consultation liaison psychiatry - catatonia - secondary psychosis - secondary mania - dissociation

Publication History

Article published online:
03 October 2024

• References

• 1 Kolappa K, Henderson DC, Kishore SP. No physical health without mental health: lessons unlearned?. Bull World Health Organ 2013; 91 (01) 3-3A
• 2 Yarmohammadi H, Dalfardi B, Ghanizadeh A, Hosseinialhashemi M. Differentiation between seizure and hysteria in a tenth-century Persian text: Hidāyat of al-Akhawayni (d. 983 AD). J Hist Neurosci 2014; 23 (04) 395-402
• 3 Oldham MA, Slooter AJC, Ely EW, Crone C, Maldonado JR, Rosenthal LJ. An interdisciplinary reappraisal of delirium and proposed subtypes. J Acad Consult Liaison Psychiatry 2023; 64 (03) 248-261
• 4 Rosenthal LJ, Khandai C. Psychotic disorders. In: Lavakumar M, Rosenthal LJ, Rabinowitz T. eds. Fundamentals of Consultation Liaison Psychiatry: Principles and Practice. 1st ed. New York: Nova Science Pub Inc.; 2019: 109-132
• 5 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013
• 6 Andersen-Ranberg NC, Poulsen LM, Perner A. et al; AID-ICU Trial Group. Haloperidol for the treatment of delirium in ICU patients. N Engl J Med 2022; 387 (26) 2425-2435
• 7 Girard TD, Exline MC, Carson SS. et al; MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med 2018; 379 (26) 2506-2516
• 8 Bowman EML, Brummel NE, Caplan GA. et al. Advancing specificity in delirium: the delirium subtyping initiative. Alzheimers Dement 2024; 20 (01) 183-194
• 9 Olivola M, Civardi S, Damiani S. et al. Effectiveness and safety of intravenous valproate in agitation: a systematic review. Psychopharmacology (Berl) 2022; 239 (02) 339-350
• 10 Gagnon DJ, Fontaine GV, Smith KE. et al. Valproate for agitation in critically ill patients: a retrospective study. J Crit Care 2017; 37: 119-125
• 11 Sherman K, Makowski C, Mahmoud A. et al. Pragmatic description of oral alpha-2 agonist SED in ICU sedation at a single tertiary care center. Crit Care Med 2023; 51 (01) 368
• 12 Fetters MB, Diep C, Ran R, Kloosterboer A. Effect of enteral guanfacine on dexmedetomidine use in the ICU. Crit Care Explor 2022; 4 (11) e0785
• 13 Vijiala S, André P, Buclin T, Decosterd LA, Rossetti AO, Novy J. Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response. Eur J Neurol 2022; 29 (09) 2607-2611
• 14 Lind J, Nordlund P. Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia. Seizure 2019; 69: 20-24
• 15 Nicholson C, Fowler M, Mullen C, Cunningham B. Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients. Epilepsy Res 2021; 178: 106806
• 16 Coupry I, Lachaud V, Podevin RA, Koenig E, Parini A. Different affinities of alpha 2-agonists for imidazoline and alpha 2-adrenergic receptors. Am J Hypertens 1989; 2 (6, Pt 1): 468-470
• 17 Howes OD, Onwordi EC. The synaptic hypothesis of schizophrenia version III: a master mechanism. Mol Psychiatry 2023; 28 (05) 1843-1856
• 18 Kelly S, Jahanshad N, Zalesky A. et al. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. Mol Psychiatry 2018; 23 (05) 1261-1269
• 19 Xu H, Yang F. The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia. Transl Psychiatry 2022; 12 (01) 464
• 20 Keshavan MS, Kaneko Y. Secondary psychoses: an update. World Psychiatry 2013; 12 (01) 4-15
• 21 Chen L, Selvendra A, Stewart A, Castle D. Risk factors in early and late onset schizophrenia. Compr Psychiatry 2018; 80: 155-162
• 22 Marneros A, Pillmann F, Wustmann T. Delusional disorders – Are they simply paranoid schizophrenia?. Schizophr Bull 2012; 38 (03) 561-568
• 23 Blackman G, Dadwal AK, Teixeira-Dias M, Ffytche D. The association between visual hallucinations and secondary psychosis: a systematic review and meta-analysis. Cogn Neuropsychiatry 2023; 28 (06) 391-405
• 24 Yagi Y, Takahashi Y, Ogata Y. et al. Oral corticosteroid dosage and clinical presentation of psychiatric conditions after steroid use: a consultation-liaison psychiatry service's experience. Neuropsychopharmacol Rep 2021; 41 (04) 471-475
• 25 Judd LL, Schettler PJ, Brown ES. et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry 2014; 171 (10) 1045-1051
• 26 Marques JG. Organic psychosis causing secondary schizophrenia in one-fourth of a cohort of 200 patients previously diagnosed with primary schizophrenia. Prim Care Companion CNS Disord 2020; 22 (02) 19
• 27 Darby R, Prasad S. Lesion-related delusional misidentification syndromes: a comprehensive review of reported cases. J Neuropsychiatry Clin Neurosci 2016; 28 (03) 217-222
• 28 Juza R, Vojtechova I, Stefkova-Mazochova K. et al. Novel D₂/5-HT receptor modulators related to cariprazine with potential implication to schizophrenia treatment. Eur J Med Chem 2022; 232: 114193
• 29 Lenka A, Pagonabarraga J, Pal PK, Bejr-Kasem H, Kulisevsky J. Minor hallucinations in Parkinson disease: a subtle symptom with major clinical implications. Neurology 2019; 93 (06) 259-266
• 30 Miller ML, Luu H, Gaasedelen O. et al. Long-term cognitive and psychological functioning in post-electroconvulsive therapy patients. J ECT 2019; 35 (01) 27-34
• 31 Tondo L, Vázquez GH, Baldessarini RJ. Depression and mania in bipolar disorder. Curr Neuropharmacol 2017; 15 (03) 353-358
• 32 Nierenberg AA, Agustini B, Köhler-Forsberg O. et al. Diagnosis and treatment of bipolar disorder: a review. JAMA 2023; 330 (14) 1370-1380
• 33 Howes OD, Falkenberg I. Early detection and intervention in bipolar affective disorder: targeting the development of the disorder. Curr Psychiatry Rep 2011; 13 (06) 493-499
• 34 Zhang H, Chen J, Fang Y. Functional alterations in patients with bipolar disorder and their unaffected first-degree relatives: insight from genetic, epidemiological, and neuroimaging data. Neuropsychiatr Dis Treat 2023; 19: 2797-2806
• 35 Osete JR, Akkouh IA, de Assis DR. et al. Lithium increases mitochondrial respiration in iPSC-derived neural precursor cells from lithium responders. Mol Psychiatry 2021; 26 (11) 6789-6805
• 36 Stern S, Santos R, Marchetto MC. et al. Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients' responsiveness to lithium. Mol Psychiatry 2018; 23 (06) 1453-1465
• 37 Mesbah R, Koenders MA, van der Wee NJA, Giltay EJ, van Hemert AM, de Leeuw M. Association between the fronto-limbic network and cognitive and emotional functioning in individuals with bipolar disorder: a systematic review and meta-analysis. JAMA Psychiatry 2023; 80 (05) 432-440
• 38 Karmacharya R, England ML, Ongür D. Delirious mania: clinical features and treatment response. J Affect Disord 2008; 109 (03) 312-316
• 39 Jacobowski NL, Heckers S, Bobo WV. Delirious mania: clinical management in the acute setting. J Psychiatr Pract 2013; 19 (01) 15-28
• 40 Restrepo-Martinez M, Ramirez-Bermudez J, Bayliss L, Espinola-Nadurille M. Delirious mania as a frequent and recognizable neuropsychiatric syndrome in patients with anti-NMDAR encephalitis. Gen Hosp Psychiatry 2020; 64: 50-55
• 41 Detweiler MB, Mehra A, Rowell T, Kim KY, Bader G. Delirious mania and malignant catatonia: a report of 3 cases and review. Psychiatr Q 2009; 80 (01) 23-40
• 42 Denysenko L, Sica N, Penders TM. et al; The Academy of Consultation-Liaison Psychiatry Evidence-Based Medicine Subcommittee Monograph. Catatonia in the medically ill: etiology, diagnosis, and treatment. Ann Clin Psychiatry 2018; 30 (02) 140-155
• 43 De Bock M, Siengert P. Corticosteroids and mania: a systematic review. World J Biol Psychiatr 2024; 25 (03) 161-174
• 44 Barahona-Corrêa JB, Cotovio G, Costa RM. et al. Right-sided brain lesions predominate among patients with lesional mania: evidence from a systematic review and pooled lesion analysis. Transl Psychiatry 2020; 10 (01) 139
• 45 Kishi T, Ikuta T, Matsuda Y. et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry 2022; 27 (02) 1136-1144
• 46 Khawam EA, Sola CL. Depressive and manic syndromes. In: Lavakumar M, Rosenthal LJ, Rabinowitz T. eds. Fundamentals of Consultation Liaison Psychiatry: Principles and Practice. 1st ed. New York: Nova Science Pub Inc; 2019: 133-170
• 47 Fann JR, Quinn DK, Hart T. Treatment of psychiatric problems after traumatic brain injury. Biol Psychiatry 2022; 91 (05) 508-521
• 48 Jorge RE, Robinson RG, Starkstein SE, Arndt SV, Forrester AW, Geisler FH. Secondary mania following traumatic brain injury. Am J Psychiatry 1993; 150 (06) 916-921
• 49 Erickson JM, Quinn DK, Shorter E. Moria revisited: translation of Moritz Jastrowitz's description of pathologic giddiness. J Neuropsychiatry Clin Neurosci 2016; 28 (02) 74-76
• 50 Leppla I, Fishman D, Kalra I, Oldham MA. Clinical approach to personality change due to another medical condition. J Acad Consult Liaison Psychiatry 2021; 62 (01) 14-21
• 51 Nash RP, Weinberg MS, Laughon SL, McCall RC, Bateman JR, Rosenstein DL. Acute pharmacological management of behavioral and emotional dysregulation following a traumatic brain injury: a systematic review of the literature. Psychosomatics 2019; 60 (02) 139-152
• 52 Walther S, Stegmayer K, Wilson JE, Heckers S. Structure and neural mechanisms of catatonia. Lancet Psychiatry 2019; 6 (07) 610-619
• 53 Rogers JP, Oldham MA, Fricchione G. et al. Evidence-based consensus guidelines for the management of catatonia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2023; 37 (04) 327-369
• 54 Oldham MA. The probability that catatonia in the hospital has a medical cause and the relative proportion of its causes: a systematic review. Psychosomatics 2018; 59 (04) 333-340
• 55 Cronemeyer M, Schönfeldt-Lecuona C, Gahr M, Keller F, Sartorius A. Malignant catatonia: Severity, treatment and outcome - a systematic case series analysis. World J Biol Psychiatry 2022; 23 (01) 78-86
• 56 Connell J, Oldham M, Pandharipande P. et al. Malignant catatonia: A review for the intensivist. J Intensive Care Med 2023; 38 (02) 137-150
• 57 Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998; 44 (06) 499-507
• 58 Smith JH, Smith VD, Philbrick KL, Kumar N. Catatonic disorder due to a general medical or psychiatric condition. J Neuropsychiatry Clin Neurosci 2012; 24 (02) 198-207
• 59 Ogyu K, Kurose S, Uchida H, Kanemoto K, Mimura M, Takeuchi H. Clinical features of catatonic non-convulsive status epilepticus: a systematic review of cases. J Psychosom Res 2021; 151: 110660
• 60 Franssen A, Sienaert P. Temporal glioblastoma presenting as catatonia. BMJ Case Rep 2019; 12 (03) e224017
• 61 Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93 (02) 129-136
• 62 Bush-Francis Catatonia Rating Scale Assessment Resources. 2024 . Accessed September 3, 2024 at: https://www.urmc.rochester.edu/psychiatry/divisions/collaborative-care-and-wellness/bush-francis-catatonia-rating-scale.aspx
• 63 Appiani FJ, Duarte JM, Sauré M. et al. Catatonia and delirium assessment of comorbidity, prevalence, and therapeutic response in medically ill inpatients from a university hospital. J Clin Psychopharmacol 2023; 43 (01) 55-59
• 64 Grover S, Ghosh A, Ghormode D. Do patients of delirium have catatonic features? An exploratory study. Psychiatry Clin Neurosci 2014; 68 (08) 644-651
• 65 Carroll BT, Boutros NN. Clinical electroencephalograms in patients with catatonic disorders. Clin Electroencephalogr 1995; 26 (01) 60-64
• 66 Arnts H, van Erp WS, Lavrijsen JCM, van Gaal S, Groenewegen HJ, van den Munckhof P. On the pathophysiology and treatment of akinetic mutism. Neurosci Biobehav Rev 2020; 112: 270-278
• 67 Beach SR, Gomez-Bernal F, Huffman JC, Fricchione GL. Alternative treatment strategies for catatonia: a systematic review. Gen Hosp Psychiatry 2017; 48: 1-19
• 68 Ludwig L, Pasman JA, Nicholson T. et al. Stressful life events and maltreatment in conversion (functional neurological) disorder: systematic review and meta-analysis of case-control studies. Lancet Psychiatry 2018; 5 (04) 307-320
• 69 Pieper S, Out D, Bakermans-Kranenburg MJ, van Ijzendoorn MH. Behavioral and molecular genetics of dissociation: the role of the serotonin transporter gene promoter polymorphism (5-HTTLPR). J Trauma Stress 2011; 24 (04) 373-380
• 70 Yu Y, Li Y, Han D. et al. Effect of dexmedetomidine on posttraumatic stress disorder in patients undergoing emergency trauma surgery: a randomized clinical trial. JAMA Netw Open 2023; 6 (06) e2318611
• 71 Singewald N, Sartori SB, Reif A, Holmes A. Alleviating anxiety and taming trauma: novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. Neuropharmacology 2023; 226: 109418
• 72 Bajor LA, Balsara C, Osser DN. An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update. Psychiatry Res 2022; 317: 114840
• 73 Villarreal G, Hamner MB, Cañive JM. et al. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. Am J Psychiatry 2016; 173 (12) 1205-1212
• 74 Guina J, Rossetter SR, DeRhodes BJ, Nahhas RW, Welton RS. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pract 2015; 21 (04) 281-303
• 75 Maercker A, Cloitre M, Bachem R. et al. Complex post-traumatic stress disorder. Lancet 2022; 400 (10345): 60-72
• 76 Posner JB, Plum F. Plum and Posner's Diagnosis of Stupor and Coma. 4th ed. Oxford; New York: Oxford University Press; 2007
• 77 Ryznar E, Wilcox D. Functional coma: two case reports and a review of the literature. Psychosomatics 2019; 60 (04) 343-351
• 78 McWhirter L, Ritchie C, Stone J, Carson A. Identifying functional cognitive disorder: a proposed diagnostic risk model. CNS Spectr 2022; 27 (06) 754-763
• 79 Cabreira V, Frostholm L, McWhirter L, Stone J, Carson A. Clinical signs in functional cognitive disorders: a systematic review and diagnostic meta-analysis. J Psychosom Res 2023; 173: 111447
• 80 Staniloiu A, Markowitsch HJ. Dissociative amnesia. Lancet Psychiatry 2014; 1 (03) 226-241
• 81 Bartsch T, Deuschl G. Transient global amnesia: functional anatomy and clinical implications. Lancet Neurol 2010; 9 (02) 205-214
• 82 Michal M, Adler J, Wiltink J. et al. A case series of 223 patients with depersonalization-derealization syndrome. BMC Psychiatry 2016; 16: 203
• 83 Carlson EB, Putnam FW, Ross CA. et al. Validity of the Dissociative Experiences Scale in screening for multiple personality disorder: a multicenter study. Am J Psychiatry 1993; 150 (07) 1030-1036
• 84 Lao KSJ, Zhao J, Blais JE. et al. Antipsychotics and risk of neuroleptic malignant syndrome: a population-based cohort and case-crossover study. CNS Drugs 2020; 34 (11) 1165-1175
• 85 Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care 2016; 24 (01) 97-103
• 86 Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother 2016; 50 (11) 973-981
• 87 Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf 1998; 19 (01) 73-82
• 88 Velamoor VR, Norman RMG, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994; 182 (03) 168-173
• 89 Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142 (10) 1137-1145
• 90 Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991; 338 (8760) 149-151
• 91 Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988; 24 (01) 25-29
• 92 Guinart D, Misawa F, Rubio JM. et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand 2021; 144 (04) 329-341
• 93 Schönfeldt-Lecuona C, Kuhlwilm L, Cronemeyer M. et al. Treatment of the neuroleptic malignant syndrome in international therapy guidelines: a comparative analysis. Pharmacopsychiatry 2020; 53 (02) 51-59
• 94 Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33 (05) 650-659
• 95 Prakash S, Rathore C, Rana K, Prakash A. Fatal serotonin syndrome: a systematic review of 56 cases in the literature. Clin Toxicol (Phila) 2021; 59 (02) 89-100
• 96 Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352 (11) 1112-1120
• 97 Nguyen H, Pan A, Smollin C, Cantrell LF, Kearney T. An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System. J Clin Pharm Ther 2019; 44 (02) 327-334
• 98 Elli C, Novella A, Pasina L. Serotonin syndrome: a pharmacovigilance comparative study of drugs affecting serotonin levels. Eur J Clin Pharmacol 2024; 80 (02) 231-237
• 99 Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96 (09) 635-642
• 100 Alapati D, Maksimowski M, Rasimus JJ. Addictions. . In: Lavakumar M, Rosenthal LJ, Rabinowitz T. eds. Fundamentals of Consultation Liaison Psychiatry: Principles and Practice. 1st ed. New York: Nova Science Pub Inc; 2019: 249-294
• 101 Maldonado JR. Novel algorithms for the prophylaxis and management of alcohol withdrawal syndromes-beyond benzodiazepines. Crit Care Clin 2017; 33 (03) 559-599
• 102 Umapathy C, Ramchandani D, Lamdan RM, Kishel LA, Schindler BA. Competency evaluations on the consultation-liaison service. Some overt and covert aspects. Psychosomatics 1999; 40 (01) 28-33
• 103 Oldham MA. Personality-informed care: speaking the language of personality. Psychosomatics 2020; 61 (03) 220-230
• 104 Iserson KV. Do you believe in magic? Shove, don't nudge: advising patients at the bedside. J Clin Ethics 2020; 31 (01) 76-78
• 105 Walter JK, Ross LF. Relational autonomy as the key to effective behavioral change. Philos Psychiatry Psychol 2013; 20 (02) 169-177
• 106 Pesanti S, Hamm B, Esplin B, Karafa M, Jimenez XF. Capacity evaluation requests in the medical setting: a retrospective analysis of underlying psychosocial and ethical factors. Psychosomatics 2017; 58 (05) 483-489
• 107 Hamm B. Psychiatric facilitation of care when requested for assessment of decision-making capacity. Psychiatr Ann 2021; 51 (03) 106-111
• 108 Perl M, Shelp EE. Sounding board. Psychiatric consultation masking moral dilemmas in medicine. N Engl J Med 1982; 307 (10) 618-621
• 109 Jones S, Howard L, Thornicroft G. ‘Diagnostic overshadowing’: worse physical health care for people with mental illness. Acta Psychiatr Scand 2008; 118 (03) 169-171
• 110 World Health Organization. Management of physical health conditions in adults with severe mental disorders: WHO guidelines [internet]. Geneva: World Health Organization, 2018 . Accessed February 11, 2024 at: https://iris.who.int/bitstream/handle/10665/275718/9789241550383-eng.pdf
• 111 Jopp DA, Keys CB. Diagnostic overshadowing reviewed and reconsidered. Am J Ment Retard 2001; 106 (05) 416-433
• 112 Hallyburton A, Allison-Jones L. Mental health bias in physical care: an integrative review of the literature. J Psychiatr Ment Health Nurs 2023; 30 (04) 649-662
• 113 Forbes M, Stefler D, Velakoulis D. et al. The clinical utility of structural neuroimaging in first-episode psychosis: a systematic review. Aust N Z J Psychiatry 2019; 53 (11) 1093-1104
• 114 Francis A, Oldham MA. Bush-Francis Catatonia Rating Scale Training Manual and Coding Guide. Accessed February 17, 2024 at: https://www.urmc.rochester.edu/MediaLibraries/URMCMedia/psychiatry/documents/BFCRS-Training-Manual-22-02-24.pdf
• 115 Substance Abuse and Mental Health Services Administration. SAMHSA's concept of trauma and guidance for a trauma-informed approach. HHS Publication No. (SMA) 14–4884. Rockville, MD: SAMHSA; 2014
• 116 Greenwald A, Kelly A, Thomas L. Trauma-informed care in the emergency department: concepts and recommendations for integrating practices into emergency medicine. Med Educ Online 2023; 28 (01) 2178366